Response to Comments: Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis

This document is an administrative Response to Comments for the Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis LCD and does not itself specify clinical coverage criteria. It notes the official notice period for the final LCD begins June 10, 2021 and the final determination becomes effective August 1, 2021.